Volume 2, Issue 2 (2022)

1. Webster RG, Govorkova EA. Continuing challenges in influenza. Ann N Y Acad Sci. 2014;1323(1):115-139. 

2. https://www.cdc.gov/flu/about/burden/preliminary-in-seasonestimates.htm 

3. Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69-89. 

4. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26(11):911-924. 

5. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-88.6. Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study. Int J Infect Dis. 2020;92:29-37. 

7. Santibanez TA, Kennedy ED. Reasons given for not receiving an influenza vaccination, 2011-12 influenza season, United States. Vaccine. 2016;34(24):2671-2678. 

8. Meyer SB, Lum R. Explanations for Not Receiving the Seasonal Influenza Vaccine: An Ontario Canada Based Survey. J Health Commun. 2017;22(6):506-514. 

9. Kaboli F, Astrakianakis G, Li G, Guzman J, Donovan T, Naus M. Influenza vaccination and intention to receive the pandemic H1N1 influenza vaccine among healthcare workers of British Columbia, Canada: a cross-sectional study. Infect Control Hosp Epidemiol. 2010;31(10):1017-1024